All In Biotech

NDA 050278 · Avet

Achromycin V

Tetracycline Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1957

Oct 8, 1957

Approved uses

1

Original approval plus efficacy supplements

Registered trials

766

141 Phase 3, 52 recruiting

FAERS reports

779

507 serious, 212 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 18, 2025.

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae. Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcalinfections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis. Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis ....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 8, 1957 Original approval
2 products under this application
  • ACHROMYCIN V · TETRACYCLINE HYDROCHLORIDE 250MG · CAPSULE, ORAL · Prescription · TE AB
  • ACHROMYCIN V · TETRACYCLINE HYDROCHLORIDE 500MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tetracycline" as an intervention, any sponsor and status, largest first.

All 766 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use226
  • drug hypersensitivity154
  • hypersensitivity125
  • pneumonia106
  • intentional product use issue104
  • pain in extremity96
  • vomiting95
  • mobility decreased94
  • arthralgia93
  • neck pain91
  • hepatitis88
  • nausea88

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20052
20062
20072
200811
20092
20109
201110
201215
20136
20145
201516
201634
201739
201826
201942
202074
202144
202255
202362
2024162
2025122
202636

Recalls

2 FDA enforcement reports for this application.

  • Mar 23, 2020 · Class I · Terminated

    Failed Dissolution Specifications: Out of specification result during long term testing in Tetracycline HCl capsules.

  • Mar 23, 2020 · Class I · Terminated

    Failed Dissolution Specifications: Out of specification result during long term testing in Tetracycline HCl capsules.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,636 on PubMed

Sponsor: Avet

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.